Surgery Partners Faces Probe Over Misleading Guidance

Edgen Stock·Mar 18 2026, 14:07

Share to

Share to

Copy link

Key Takeaways

Law firm Levi & Korsinsky, LLP has initiated an investigation into Surgery Partners (SGRY), questioning whether the company misled investors with overly optimistic financial guidance. The probe follows a significant stock price decline after the company failed to meet Q4 2025 earnings expectations and lowered its outlook for fiscal year 2026.

Law firm Levi & Korsinsky, LLP launched an investigation into Surgery Partners (SGRY) on March 18, 2026.
The action follows a sharp stock decline in early March 2026 after the company's Q4 2025 results and FY 2026 outlook disappointed investors.
At issue is whether management concealed known cost pressures while publicly guiding for "margin expansion in 2025 and beyond."

Outlook Downgrade Sparks Shareholder Investigation

Surgery Partners (NASDAQ: SGRY) is now the subject of a shareholder investigation after its stock fell sharply in early March 2026. The sell-off was triggered when the company's fourth-quarter 2025 results and its full-year 2026 financial outlook both failed to meet market expectations. In response, law firm Levi & Korsinsky, LLP announced on March 18, 2026, that it is investigating whether the company's prior forward-looking statements violated securities laws.

CEO's 2024 Margin Guidance Faces Scrutiny

The investigation centers on potentially misleading guidance regarding the company's profitability. During the Q4 2024 earnings call, CEO Eric Evans assured investors, stating, "we continue to expect margin expansion in 2025 and beyond." However, the subsequent earnings miss and guidance downgrade suggest the company faced significant headwinds. The probe aims to determine if management was aware of undisclosed cost pressures and operational risks that made its positive guidance on margins unattainable, thereby misleading shareholders about the company's true financial health.

Legal Risk Adds Pressure to SGRY Stock

The initiation of this investigation exposes Surgery Partners to significant legal and reputational risk. If the probe uncovers evidence of wrongdoing, it could escalate into a class-action lawsuit, potentially leading to financial penalties and further damaging investor confidence. This legal overhang creates another layer of uncertainty for the stock, which is already under pressure from its poor operational performance. Investors will now closely monitor for any formal legal filings or further statements from the company addressing the allegations.